alphaveAPOLLOHOSP₹8,894.00

Apollo Hospitals Enterprise Ltd.

Annual Quarterly₹ CrorePeersFORTIS MAXHEALTH MEDANTA SUNPHARMA CIPLA DRREDDY DIVISLAB TORNTPHARMMcap ₹1.28L Cr

View

In ₹ Crore except Per Share 12 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	4,846.9	4,850.6	4,943.9	5,085.6	5,589.3	5,526.9	5,592.2	5,842.1	6,303.5	6,477.4	6,605.5	7,043.5
Other Income	22.2	27.8	28.1	37.2	38.2	63.8	61.1	40.2	54.7	52.8	43.9	48.8
Total Income	4,869.1	4,878.4	4,972.0	5,122.8	5,627.5	5,590.7	5,653.3	5,882.3	6,358.2	6,530.2	6,649.4	7,092.3
Expenses
+ Cost of Materials Consumed	632.5	603.3	637.5	690.1	744.3	625.6	694.4	740.1	778.7	744.6	777.4	829.0
+ Purchases of Stock-in-Trade	1,840.5	1,943.6	1,914.1	1,910.7	2,110.4	2,292.0	2,243.6	2,315.5	2,464.7	2,663.1	2,613.1	2,767.8
+ Changes in Inventories	-14.5	-13.8	-5.9	22.2	3.0	-16.9	-9.4	-8.0	0.2	-25.3	11.5	0.3
+ Employee Benefit Expense	644.1	612.9	644.9	658.1	700.1	686.4	724.6	712.6	766.7	749.0	772.0	795.8
+ Finance Costs	111.3	112.6	119.3	116.4	117.5	109.8	114.8	108.3	109.6	112.6	119.1	120.4
+ Depreciation & Amortisation	163.4	167.0	189.7	177.4	184.5	184.6	211.0	214.7	217.8	219.2	224.4	235.1
+ Other Expenses	1,116.8	1,090.9	1,112.8	1,129.4	1,216.0	1,178.3	1,169.3	1,230.0	1,352.1	1,380.7	1,420.5	1,558.5
Total Expenses	4,494.1	4,516.5	4,612.4	4,704.3	5,075.8	5,059.8	5,148.3	5,313.2	5,689.8	5,843.9	5,938.0	6,306.9
EBITDA	627.5	613.7	640.5	675.1	815.5	761.5	769.7	851.9	941.1	965.3	1,011.0	1,092.1
EBIT	464.1	446.7	450.8	497.7	631.0	576.9	558.7	637.2	723.3	746.1	786.6	857.0
Profit
PBT before Exceptional Items	375.0	361.9	359.6	418.5	551.7	530.9	505.0	569.1	668.4	686.3	711.4	785.4
+ Exceptional Items	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-19.2	0.0	0.0
Pretax Income	376.9	361.9	359.6	418.5	551.7	530.9	505.0	569.1	668.4	667.1	711.4	785.4
+ Current Tax	132.5	113.2	88.7	113.0	159.8	134.5	119.0	124.8	161.5	147.0	196.0	210.3
+ Deferred Tax	-2.3	-4.3	21.1	1.5	1.9	22.3	-18.0	16.9	19.2	18.7	-25.8	-21.9
Tax Expense	130.2	108.9	109.8	114.5	161.7	156.8	101.0	141.7	180.7	165.7	170.2	188.4
+ Share of Associates & JVs	2.1	1.4	8.6	11.5	5.7	5.3	10.5	13.6	6.3	14.9	10.1	13.4
Net Income	248.8	254.4	258.4	315.5	395.7	379.4	414.5	441.0	494.0	516.3	551.3	610.4
+ Net Income — Continuing Ops	246.7	253.0	249.8	304.0	390.0	374.1	404.0	427.4	487.7	501.4	541.2	597.0
+ Other Comprehensive Income	-9.3	0.8	-0.2	5.2	-5.5	-2.9	-3.0	5.9	56.8	-0.2	-4.1	3.9
Total Comprehensive Income	239.5	255.2	258.2	320.7	390.2	376.5	411.5	446.9	550.8	516.1	547.2	614.3
Net Income to Common	232.9	245.3	253.8	305.2	378.8	372.3	389.6	432.8	477.2	502.3	529.3	580.7
Minority Interest	15.9	9.1	4.6	10.3	16.9	7.1	24.9	8.2	16.8	14.0	22.0	29.7
Per Share
Basic EPS	16.20	17.06	17.65	21.23	26.34	25.89	27.10	30.10	33.19	34.94	36.82	40.39
Diluted EPS	16.20	17.06	17.65	21.23	26.34	25.89	27.10	30.10	33.19	34.94	36.76	40.37
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	-3.0	5.9	56.8	-0.2	-4.1	3.9
+ Items NOT to be Reclassified to P&L	-13.0	1.2	-0.3	5.2	-6.6	-3.4	-3.8	6.1	65.3	-0.9	-8.6	4.0
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.9	0.2	9.6	-0.3	-3.1	0.2
+ Tax on Items NOT to be Reclassified — alt tag	-3.3	0.3	-0.1	0.0	-0.9	0.1	—	—	—	—	—	—
+ Items to be Reclassified to P&L	0.4	-0.1	0.0	—	0.2	0.6	-0.1	0.0	1.1	0.4	1.4	0.1
Comprehensive Income — Owners of Parent	223.7	246.4	-0.4	310.4	374.0	369.5	387.1	438.8	533.7	502.2	524.6	584.7
Comprehensive Income — Non-controlling Interests	15.8	8.8	0.2	10.3	16.2	7.0	24.4	8.1	17.1	13.9	22.6	29.6
Per Share — as-filed variants
Basic EPS — Continuing Operations	16.20	17.06	17.65	21.23	26.34	25.89	27.10	30.10	33.19	34.94	36.82	40.39
Diluted EPS — Continuing Operations	16.20	17.06	17.65	21.23	26.34	25.89	27.10	30.10	33.19	34.94	36.76	40.37
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	2,388.4	2,317.5	2,398.2	2,462.6	2,731.6	2,626.2	2,663.6	2,794.5	3,059.9	3,095.0	3,203.5	3,446.4
Gross Margin %	49.28	47.78	48.51	48.42	48.87	47.52	47.63	47.83	48.54	47.78	48.50	48.93
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	375.0	361.9	359.6	418.5	551.7	530.9	505.0	569.1	668.4	686.3	711.4	785.4
− Exceptional Items (reconciliation)	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-19.2	0.0	0.0
Net Income Adj (tax-effected)	247.6	254.4	258.4	315.5	395.7	379.4	414.5	441.0	494.0	530.7	551.3	610.4
EPS Adj	16.12	17.06	17.65	21.23	26.34	25.89	27.10	30.10	33.19	35.92	36.82	40.39
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00	5.00	5.00	5.00	10.00	5.00	10.00	5.00	5.00	5.00
Paid Up Equity Capital	71.9	71.9	71.9	71.9	71.9	71.9	71.9	71.9	71.9	71.9	71.9	71.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.